Skip to content
drillr.ai

RARE

Ultragenyx Pharmaceutical Inc.

NASDAQ · USHealthcareBiotechnology
$28.53-2.56%

Price as of Jul 20, 2026

RARE news

Ultragenyx Pharmaceutical Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Ultragenyx Pharmaceutical Inc. (RARE)

    SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) against certain of its officers and directors for alleged breaches of fiduciary duty. Shareholders who have held Ultragenyx shares continuously since prior to August 3, 2023, may have standing to seek corporate governance reforms, the return of funds back to the company, and a court-approved incentive aw

    Globe Newswire ·

  2. Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact

    NOVATO, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its 2025 Impact Report (https://www.globenewswire.com/Tracker?data=djHjenEnebWgQUWMQQKAfj2sCKYmv5aRTB-9eVtyHG0vfH7qPpkZ0DN088Dx_fm39Vx6wbRu3xfGNcBCv6FPB0Db4En0IiOf8-dyHvySmqTf2SpgoOR8E7PZPeaDqio6uJPx5MDR4g1gHy2LKjPNB9eugfzjVH59LZ1vqftiAmY=), detailing the company's work on behalf of patients and families living with rare and ultra-rare diseases. In 2025, Ultragenyx advanced five investigation

    Globe Newswire ·

  3. Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    NOVATO, Calif., June 19, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 44,409 restricted stock units of the company’s common stock to 15 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Empl

    Globe Newswire ·

  4. Lifshitz Law PLLC Announces Investigations of Kyndryl Holdings, Inc. (NYSE: KD), Corcept Therapeutics, Inc. (NASDAQ: CORT), NuScale Power Corporation (NYSE: SMR), and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / June 4, 2026 / Lifshitz Law Firm Kyndryl Holdings, Inc. (NYSE:KD) Lifshitz Law PLLC (https://pr.report/UYyV-38n) announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made false and/or misleading statements and/or failed to disclose that: (i) Kyndryl's financial statements issued during the Relevant Period were materially misstat

    ACCESSWIRE ·

  5. Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm

    Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm PR Newswire NEW YORK, June 4, 2026 NEW YORK, June 4, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) breached their fiduciary duties to shareholders. (https://mma.prnewswire.com/media/2309909/Kuehn_Law_PLLC.html) According to a federal securities lawsuit, Insiders at Ultragenyx P

    PR Newswire ·

  6. Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference

    NOVATO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil Kakkis, M.D., Ph.D., the company's president and chief executive officer will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, at 4:00 PM ET. The live and archi

    Globe Newswire ·

  7. Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update

    First quarter total revenue of $136 million, Crysvita® revenue of $93 million and Dojolvi® revenue of $18 million Reaffirm 2026 financial guidance, including total revenue of $730 million to $760 million and combined R&D and SG&A expenses to be flat to slightly down versus 2025; remain on path to profitability in 2027 GTX-102 for Angelman syndrome: New longer-term data from Phase 1/2 clinical study support durable and improving effects across multiple domains; Phase 3 data expected in the seco

    Globe Newswire ·

  8. Lifshitz Law PLLC Announces Investigations of Inovio Pharmaceuticals, Inc. (NASDAQ: INO), Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), Oracle Corporation (NYSE: ORCL), and BlackRock, TCP Capital Corp. (NASDAQ: TCPC)

    NEW YORK, NY / ACCESS Newswire (https://www.accessnewswire.com/) / April 15, 2026 / Lifshitz Law Firm Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Lifshitz Law PLLC (https://pr.report/UTMC7BaH) announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made false and/or misleading statements and/or failed to disclose that: (i) manufacturing for Inovio's CELLECTRA device was deficient; (ii) accordingly, Inovi

    ACCESSWIRE ·

  9. RARE CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026

    Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson (https://api.newsfilecorp.com/redirect/WABoeIMV1O) Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Ultragenyx (https://api.newsfilecorp.com/redirect/qpV5XUKAVx) between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-93

    Newsfile Corp ·

  10. Lifshitz Law PLLC Announces Investigations of REGENXBIO Inc. (NASDAQ: RGNX), Kyndryl Holdings, Inc. (NYSE: KD), Inovio Pharmaceuticals, Inc. (NASDAQ: INO), and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / April 7, 2026 / Lifshitz Law Firm REGENXBIO Inc. (NASDAQ:RGNX) Lifshitz Law PLLC (https://pr.report/kQ3belhL) announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) REGENXBIO's representations concerning its plan to develop and commercialize RGX‑1

    ACCESSWIRE ·

  11. Pomerantz LLP Advises Shareholders of Class Action Involving Ultragenyx Pharmaceutical Inc. – RARE

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / April 6, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ:RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares pur

    ACCESSWIRE ·

  12. RARE DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - RARE

    New York, New York--(Newsfile Corp. - April 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purchased Ultragenyx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a

    Newsfile Corp ·

  13. RARE DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - RARE

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / April 6, 2026 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purchased Ultragenyx common stock during the Class Period you may be entitled to compensation without payment of any out of

    ACCESSWIRE ·

  14. ULTRAGENYX URGENT DEADLINE: Bragar Eagel & Squire, P.C. Reminds Ultragenyx (NASDAQ:RARE) Investors of the April 6th Lead Plaintiff Deadline and Urges Investors to Contact the Firm

    Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker (https://www.globenewswire.com/Tracker?data=3JzyZk69yJtQtqZA9OIb6KBchdCcurNK0iOINxoRwl12GiLFSgtJ97UK9a2HMI9I5pCOKD48Yv-NCmA-DKTRzc0mr_lLx04VFejoANSMke5mdKFH7Nx5ORloTGfLS1wT) Encourages Investors Who Suffered Losses In Ultragenyx (RARE) To Contact Him Directly To Discuss Their Options If you purchased or acquired Ultragenyx common stock between August 3, 2023, to December 26, 2025, and would like to discuss your legal rights, call Brag

    Globe Newswire ·

  15. RARE FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026

    RARE FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.faruqilaw.com%2Fattorney%2F22%2Fjames-m-wilson-jr&esheet=54478989&newsitemid=20260406247253&lan=en-US&anchor=James+%28Josh%29+Wilson&index=1&md5=5ccddcac0438a600950dbdbdc119c931) Encourages Investors Who Su

    Business Wire ·

  16. RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm

    RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire LOS ANGELES, April 6, 2026 LOS ANGELES, April 6, 2026 /PRNewswire/ -- The Schall Law Firm (https://edge.prnewswire.com/c/link/?t=0&l=en&o=4657469-1&h=2611777568&u=https%3A%2F%2Fschallfirm.com%2F&a=The+Schall+Law+Firm) , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or

    PR Newswire ·

  17. Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE

    Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE PR Newswire LOS ANGELES, April 6, 2026 LOS ANGELES, April 6, 2026 /PRNewswire/ -- The DJS Law Group (https://edge.prnewswire.com/c/link/?t=0&l=en&o=4657470-1&h=4069851664&u=https%3A%2F%2Fdjslawllp.com%2F&a=The+DJS+Law+Group) reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or "the Company") (NASDAQ: RARE (https://edge.prnewswi

    PR Newswire ·

  18. Ultragenyx 24 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE

    NEW YORK, NY AND NEW ORLEANS, LA / ACCESS Newswire (https://www.accessnewswire.com/) / April 5, 2026 / Kahn Swick & Foti, LLC (https://pr.report/kevm) ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 6, 2026 to file lead plaintiff applications in a securities class action lawsuit against Ultragenyx Pharmaceutical (https://pr.report/kevn) Inc. ("Ultragenyx" or the "Company") (NasdaqGS:RARE), if they purchased or o

    ACCESSWIRE ·

  19. RARE DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - RARE

    NEW YORK, April 05, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the “Class Period”), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purchased Ultragenyx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingenc

    Globe Newswire ·

  20. Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm

    NEW YORK, April 05, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Ultragenyx securities between August 3, 2023 an

    Globe Newswire ·